靶向重度哮喘的生物制剂研究进展  

Research progress in biological agents targeting severe asthma

作　　者：崔雪萍 彭红艳 刘灵敏 姜承奇 Cui Xueping;Peng Hongyan;Liu Lingmin;Jiang Chengqi(Department of Respiratory and Critical Care Medicine,Qujing Hospital Affiliated to Kunming Medical University/Qujing First People's Hospital/Yunnan Provincial Regional Medical Center Qujing Central Hospital,Qujing 655000,China;Department of Clinical Pharmacy,Qujing Hospital Affiliated to Kunming Medical University/Qujing First People's Hospital/Yunnan Provincial Regional Medical Center Qujing Central Hospital,Qujing 655000,China;Department of Thoracic Surgery,Qujing Hospital Affiliated to Kunming Medical University/Qujing First People's Hospital/Yunnan Provincial Regional Medical Center Qujing Central Hospital,Qujing 655000,China)

机构地区：[1]昆明医科大学附属曲靖医院/云南省曲靖市第一人民医院/云南省区域医疗中心曲靖中心医院呼吸与危重症医学科,云南曲靖655000 [2]昆明医科大学附属曲靖医院/云南省曲靖市第一人民医院/云南省区域医疗中心曲靖中心医院临床药学科,云南曲靖655000 [3]昆明医科大学附属曲靖医院/云南省曲靖市第一人民医院/云南省区域医疗中心曲靖中心医院胸外科,云南曲靖655000

出　　处：《实用药物与临床》2024年第6期457-462,共6页Practical Pharmacy and Clinical Remedies

基　　金：曲靖市第一人民医院院级科研课题(NO.2023YJKTF22)。

摘　　要：支气管哮喘是一种常见的慢性气道炎症疾病,约90%未控制的哮喘由2型炎症驱动。在我国,68%的重度哮喘为2型炎症型哮喘。2023年GINA指南强调推荐采取个体化靶向治疗重度哮喘,瞄准疾病炎症本质,采取精准治疗策略。当前靶向重度2型炎症型哮喘的生物制剂已成为研究热点,已有6种靶向2型炎症为主的生物制剂被获批应用于临床,包括抗IgE抗体(奥马珠单抗)、抗IL-5/IL-5R抗体(美泊利单抗、瑞利珠单抗、本瑞利珠单抗)、抗IL-4R抗体(度普利尤单抗)和抗TSLP抗体(特泽佩鲁单抗)。本文综述靶向重度哮喘的生物制剂的研究进展。Asthma is a common form of chronic airway inflammation.About 90%of uncontrolled asthma is driven by type 2 inflammation,which accounts for 68%of severe asthma in China.The 2023 GINA guidelines emphasize the need for individualized and targeted treatment of severe asthma,targeting the inflammatory nature of the disease and creating precision treatment strategies.Currently,biologics targeting severe type 2 inflammatory asthma have become a research hotspot,and six biologics targeting type 2 inflammation have been approved for clinical application,which include anti-IgE antibody(omalizumab),anti-IL-5/IL-5R antibody(mepolizumab,reslizumab and benralizumab),anti-IL-4R antibody(dupilumab)and anti-TSLP antibody(tezepelumab).This article reviews the research progress of biological agents targeting severe asthma.

关 键 词：靶向制剂 哮喘 抗IGE抗体 抗IL-5/IL-5R抗体 抗IL-4R抗体 抗TSLP抗体 

分 类 号：R974[医药卫生—药品]